Insmed Inc (INSM)vsNRX Pharmaceuticals Inc (NRXP)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
NRXP
NRX Pharmaceuticals Inc
$2.13
+20.34%
HEALTHCARE · Cap: $58.96M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 250488% more annual revenue ($606.42M vs $242,000). NRXP leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
NRXP
Avoid21
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : NRXP
NRXP has a balanced fundamental profile.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : NRXP
The primary concerns for NRXP are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while NRXP is a value play — different risk/reward profiles.
NRXP carries more volatility with a beta of 1.99 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
NRXP generates stronger free cash flow (-4M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 21/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
NRX Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
NRx Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops new treatments for the treatment of life-threatening central nervous system disorders and lung diseases. The company is headquartered in Wilmington, Delaware.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?